Maizinol vs Melatonin: What the Research Actually Shows About Deep Sleep

If you have searched for sleep supplements in India, you have almost certainly landed on melatonin. It is the dominant ingredient in the category, widely sold, and frequently recommended.

But in the past two years, a different ingredient has started appearing in clinical literature: Maizinol, a standardised extract of Zea mays (corn leaf) developed under the trade name UP165. Its mechanism is different. Its target is different. And for a specific subset of people — those who can fall asleep but wake up tired, feel unrefreshed in the morning, or show low deep-sleep readings on a smartwatch — the distinction matters.

This article compares both ingredients directly: how they work, what the research shows, and which problem each is actually designed to solve.

What Melatonin Actually Does

Melatonin is a hormone produced by the pineal gland in response to darkness. Its job is not to produce sleep itself — it is a circadian signal. It tells your body that night has arrived and that the conditions for sleep are present.

When you take melatonin as a supplement, you are adding exogenous (external) hormone to that signalling system. This is useful in specific circumstances: crossing time zones, shift work, or situations where your light exposure has shifted your clock out of phase with your intended sleep time.

What melatonin does not do well is improve the architecture of sleep once you are asleep. It does not increase the proportion of N3 (deep, slow-wave) sleep. It does not meaningfully lower overnight cortisol. And because it is a hormone, daily supplementation can, in some people, lead to the body producing less of its own melatonin over time — the standard physiological response to consistent external hormone supply.

A 2022 review in Sleep Medicine Reviews (Auger et al.) noted that while melatonin is effective for circadian rhythm disorders, its evidence base for improving sleep quality in otherwise healthy adults with non-circadian sleep complaints is significantly weaker than its market presence suggests.

What Maizinol (UP165) Is and How It Works

Maizinol is a proprietary extract of Zea mays (corn leaf) standardised to its active constituent 6-methoxybenzoxazolinone (6-MBOA). It was developed by Unigen and has been studied under the designation UP165.

Its mechanism operates through two pathways:

Critically, Maizinol is not a hormone. It does not add exogenous melatonin to your system. Some early research suggests it may support endogenous melatonin synthesis — the body making more of its own — but this is a secondary effect, not its primary mechanism.

Maizinol vs Melatonin: Side-by-Side

What the Clinical Research Shows

The Talbott et al. (2023) Trial

The primary published trial for Maizinol UP165 was conducted by Talbott and colleagues and published in the Journal of the International Society of Sports Nutrition (2023). The design: 45 participants, double-blind, placebo-controlled, 8-week duration, 250mg of UP165 per day.

Key results in the Maizinol group versus placebo:

An important note on methodology: the trial used wearable EEG rather than clinical polysomnography (Level 1 PSG), which is the gold standard for sleep architecture research. Wearable EEG is validated and used in peer-reviewed research, but it carries more measurement variance than in-lab PSG. The trial should be interpreted accordingly — as promising and well-designed, not as definitive clinical proof equivalent to pharmaceutical-level trials.

The Doma et al. (2026) Trial

A more recent trial (Doma et al., 2026) examined a 500mg dose of Maizinol UP165 and reported a different effect size on deep sleep. This trial used a different study population and design, and the higher dose produced different outcomes than the 250mg trial. For individuals looking at commercial products, it is worth confirming which dose a given formulation uses, since the two trials are not directly comparable.

Melatonin's Evidence Base

Melatonin has a much larger body of research. It is well-established for jet lag and circadian rhythm disorders (the Cochrane systematic review, Herxheimer and Petrie, confirmed this across 10 trials). For general insomnia, the picture is more mixed. A 2013 Cochrane review found a statistically significant but "modest" improvement in sleep onset latency (about 7 minutes) and total sleep time (about 8 minutes) in adults with primary insomnia. Meaningful, but not transformative for people whose primary complaint is sleep quality rather than difficulty initiating sleep.

Which One Is Right for You?

These two problems are more common than many people realise. In the Journal of Clinical Sleep Medicine, Kaur and colleagues (2023) found that non-restorative sleep — defined as sleeping adequate hours but not feeling rested — affects a significant proportion of adults who would not describe themselves as insomniacs. They fall asleep. They just do not recover.

Why the Cortisol Difference Matters

One of the least appreciated reasons for poor sleep quality in working adults is chronic low-grade cortisol elevation. You cannot sedate a threat-detection system offline. You have to convince it that it is safe.

Melatonin does not directly address elevated cortisol. It is a downstream signal: it tells your body the time, but if your threat-detection system is still running hot — because of screen exposure, deadline pressure, or the general background load of modern professional life — melatonin will not fully resolve what is happening in your sleep architecture.

Maizinol's cortisol-reduction effect is why, for people with screen-heavy, high-cognitive-load schedules, the mechanism is potentially better matched to their actual problem. The 36% cortisol reduction observed in the Talbott trial is not a minor secondary effect — it is likely central to why deep sleep improved.

Frequently Asked Questions

What is Maizinol and how does it differ from melatonin?

Maizinol (UP165) is a standardised plant extract from Zea mays (corn leaf) that supports deep sleep through the GABAergic system and cortisol reduction. Melatonin is a hormone that signals sleep onset. The key difference: melatonin helps you fall asleep but does not improve deep sleep architecture, while Maizinol targets N3 (deep) sleep quality directly. Maizinol is non-hormonal and does not suppress your body's own melatonin production.

Is Maizinol better than melatonin?

It depends on what you need. Melatonin is useful for circadian disruption and jet lag. Maizinol is designed for a different problem: improving the quality of deep (N3) sleep and supporting overnight recovery. They address different parts of the sleep process. If you fall asleep reasonably well but wake up tired, Maizinol targets the problem more directly.

Does Maizinol have side effects?

In the published clinical trial at 250mg (Talbott et al., 2023, n=45, 8 weeks), Maizinol UP165 was well tolerated with no significant adverse events reported. Unlike melatonin, it is non-hormonal and does not interfere with the body's own melatonin synthesis. Individual responses vary. Consult a doctor before use if you are pregnant, breastfeeding, under 18, or on prescription medication.

Can you take Maizinol and melatonin together?

There is no published research on combining Maizinol with exogenous melatonin. Since Maizinol works partly by supporting the body's own melatonin synthesis, adding exogenous melatonin simultaneously may not be necessary. Consult a healthcare professional before combining supplements.

What dose of Maizinol is clinically studied?

The Talbott et al. (2023) trial used 250mg of Maizinol UP165 per day over 8 weeks. A separate trial (Doma et al., 2026) used 500mg. Most commercial formulations use 250mg, the dose from the first published trial. If you are evaluating a product, check that the label specifies UP165 and lists the dose clearly.